keepontruckin
Senior Member
- Messages
- 216
This is a translation from the following German web site.
Berlin Cures has developed the drug BC 007 that renders GPCR autoantibodies harmless in the blood of patients. Since a connection between ME / CFS and autoantibodies has been confirmed by research, a therapy of ME / CFS patients with BC 007 is very obvious.
UK Erlangen will soon test the effect of the drug on Long Covid patients as part of a study, research funds have been made available.
The UK Erlangen has also agreed to investigate the effect of the drug in ME / CFS patients. However, there is a lack of € 800,000 in research funding.
My question: For what reasons is the study not also being funded for ME / CFS patients?
From my point of view, the BMBF is required to make this sum available at short notice. Especially against the background of the decades of neglect of ME / CFS research and ME / CFS patients and the EU resolution on ME / CFS of June 17th, 2020.
https://fragdenstaat.de/anfrage/studie-zu-bc-007-mit-mecfs-patienten/
Berlin Cures has developed the drug BC 007 that renders GPCR autoantibodies harmless in the blood of patients. Since a connection between ME / CFS and autoantibodies has been confirmed by research, a therapy of ME / CFS patients with BC 007 is very obvious.
UK Erlangen will soon test the effect of the drug on Long Covid patients as part of a study, research funds have been made available.
The UK Erlangen has also agreed to investigate the effect of the drug in ME / CFS patients. However, there is a lack of € 800,000 in research funding.
My question: For what reasons is the study not also being funded for ME / CFS patients?
From my point of view, the BMBF is required to make this sum available at short notice. Especially against the background of the decades of neglect of ME / CFS research and ME / CFS patients and the EU resolution on ME / CFS of June 17th, 2020.
https://fragdenstaat.de/anfrage/studie-zu-bc-007-mit-mecfs-patienten/